EP Patent

EP0278040B1 — Verwendung von Pteridinen und/oder Purinen oder eines Xanthinoxidase-Hemmers zur Herstellung eines Arzneimittels zur Behandlung von genetisch bedingten degenerativen Netzhauterkrankungen

Assigned to Pharm Allergan GmbH · Expires 1991-08-14 · 35y expired

What this patent protects

Patent listed against sapropterin-dihydrochloride.

Drugs covered by this patent

sapropterin-dihydrochloride (SAPROPTERIN DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP0278040B1
Jurisdiction: EP
Classification: —
Expires: 1991-08-14
Drug substance claim: No
Drug product claim: No
Assignee: Pharm Allergan GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.